Timberlyne Therapeutics
Timberlyne Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for autoimmune disorders. Their lead program, CM313, is a monoclonal antibody targeting CD38, showing promising results in treating various autoimmune diseases and cancers. The company was formed through a partnership between Mountainfield Venture Partners and Keymed Biosciences.
Buy Funded Startups lists
Funding Round: Series A
Funding Amount: $180M
Date: 09-Jan-2025
Investors: Abingworth, Bain Capital Life Sciences, Venrock Healthcare Capital Partners, Boyu Capital, Lilly Asia Ventures, Braidwell LP, 3H Health Investment
Markets: Biopharma, Biotechnology, Health Care
HQ: San Diego, California, United States
Founded: 2024
Website: https://timberlyne-tx.com
LinkedIn: https://www.linkedin.com/company/timberlyne-therapeutics
Crunchbase: https://www.crunchbase.com/organization/timberlyne-therapeutics
Leave a Comment
Comments
No comments yet.